Trial Profile
A Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination With Anti-PD-1 Therapy in Adult Patients With Unresectable or Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jun 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; SER-401 (Primary) ; Vancomycin
- Indications Malignant melanoma; Skin cancer
- Focus Adverse reactions
- Acronyms MCGRAW
- 07 Jun 2022 Status changed from discontinued to completed.
- 11 May 2022 Planned End Date changed from 1 Mar 2023 to 1 Sep 2022.
- 06 Dec 2021 Planned End Date changed from 1 Jan 2023 to 1 Mar 2023.